


## Modelling Shows the Potential of LA-PrEP



Adapted from Lenacapavir: Preliminary impact, cost effectiveness and cost threshold for South Africa, presented to the South African PrEP Technical Working Group in 2024 by Lise Jamieson, Gesine Meyer-Rath and Leigh Johnson.